tbuckley/cabot-search huggingface dataset:
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
Authors: Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M. Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry A. Rogers, Sameer A. Parikh, Steven Coutre, Arti Hurria, Jennifer R. Brown, Gerard Lozanski, James S. Blachly, Hatice G. Ozer, Brittny Major-Elechi, Briant Fruth, Sreenivasa Nattam, Richard A. Larson, Harry Erba, Mark Litzow, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Richard F. Little, Scott E. Smith, Richard M. Stone, Sumithra J. Mandrekar, John C. Byrd
Journal: New England Journal of Medicine (2018)

Ibrutinib has been approved by the Food and Drug Administration for the treatment of patients with untreated chronic lymphocytic leukemia (CLL) since 2016 but has not been compared with chemoimmunotherapy. We conducted a phase 3 trial to evaluate the efficacy of ibrutinib, either alone or in combination with rituximab, relative to chemoimmunotherapy.
Robot-assisted Vescica Ileale Padovana: A New Technique for Intracorporeal Bladder Replacement Reproducing Open Surgical Principles
Authors: Giovanni E. Cacciamani, Vincenzo De Marco, Marco Sebben, Riccardo Rizzetto, Maria A. Cerruto, Antonio B. Porcaro, Inderbir S. Gill, Walter Artibani
Journal: European Urology (2018)
Mechanisms Underlying Augmented Lymphomagenesis by LUBAC; Possible Accumulation of AID-Mediated Somatic Mutations
Authors: Tomoyasu Jo, Momoko Nishikori, Yoshiteru Sasaki, Yasunori Kogure, Keisuke Kataoka, Seishi Ogawa, Kazuhiro Iwai, Akifumi Takaori-Kondo
Journal: Blood (2018)
Complementary and integrative medicine use for individuals seeking conventional medical oncology care in Chile: Prevalence and patient characteristics.
Authors: Gabriel Lopez, Claudio Alejandro Salas, Fernando Cadiz, Carolina Barriga, Pilar Gonzalez, Sandra Acevedo, Patricia Raimilla, Pia Pincheira, Aung Naing, Marta Quiroga
Journal: Journal of Clinical Oncology (2018)

110 Background: Complementary and integrative medicine (CIM) use during cancer care has increased in western medical settings. Little is known about interest in and use of CIM approaches by oncology patients in South America. Methods: Patients presenting for conventional outpatient or inpatient medical oncology care at the Clinica Alemana in Santiago, Chile (March-June, 2017) were asked to complete a survey about their interest in and use of CIM approaches. Goals included determining prevalence of CIM use and exploring associations between CIM use and patient characteristics. Statistical analyses included two-tailed t-test for continuous variables, Fischer’s exact test for categorical variables, and logistic regression for association between CIM use and other variables. Results: Of 432 patients surveyed, 66.7% had a diagnosis of breast cancer, 84.8% were women, the majority between ages 40-60 (32.7%). Of those surveyed, 221 (51.5%) reported CIM use. No association was found between CIM use and sociodemographic variables (sex, age, education, income). Patients with breast cancer (44.6%) reported CIM use, compared to 64.8% of other cancer types (p=0.0001). Most commonly reported CIM types used included herbals (49.1%), vitamins/minerals (40.8%), prayer/meditation (40.4%), and special diets (38.5%). Most frequent reasons for CIM use included “do everything possible” (72%), “improve my immune function” (67.8%), “reduce treatment related side effects” (32.7%), and “recommended by family/friend” (32.7%). Most (43.4%) reported starting CIM use at the time of cancer diagnosis, with only 55.4% sharing information regarding CIM use with their medical team. Majority reported benefits from CIM use (60%). No differences were observed in self-reported quality of life between those using versus not using CIM. Conclusions: The majority of patients receiving conventional oncology care reported engaging in CIM use, with just over half of users communicating with their oncology team about their CIM use. Increased awareness of regional differences in CIM use may help increase communication regarding this topic and contribute to improved outcomes.
Nanosonosensitizers for Highly Efficient Sonodynamic Cancer Theranostics
Authors: Ju Huang, Fengqiu Liu, Xiaoxia Han, Liang Zhang, Zhongqian Hu, Qinqin Jiang, Zhigang Wang, Haitao Ran, Dong Wang, Pan Li
Journal: Theranostics (2018)

Multifunctional nanoplatforms with diagnostic-imaging and targeted therapeutic functionality (theranostics) are of great interest in the field of precision nanomedicine. The emerging sonodynamic therapy (SDT) combined with sonosensitizers under the guidance of photoacoustic (PA) imaging is highly expected to accurately eliminate cancer cells/tissue.
A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML): Alliance Clinical Trials in Oncology (Alliance) Historical Patient Control
Authors: Alice S. Mims, Jessica Kohlschmidt, Uma Borate, Brianna Norris, Taylor Bucy, James S. Blachly, Shelley Orwick, Ann-Kathrin Eisfeld, Dimitrios Papaioannou, Deedra Nicolet, Krzysztof Mrózek, Bhavana Bhatnagar, Eytan M. Stein, Richard M. Stone, Jonathan E. Kolitz, Eunice S. Wang, Bayard L. Powell, Amy Burd, Ross L. Levine, Brian J. Druker, Clara D. Bloomfield, John C. Byrd
Journal: Blood (2018)
AB1369 Elevated ca-125 in igg4-related mesenteric disease: a red herring? a systematic literature review
Authors: I. Panayotidis, M. Michaud Maturana, S. Psarelis, E. Nikiphorou
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Mesenteric panniculitis (MP), a rare fibrotic inflammatory disease of the bowel mesentery, can be a rare manifestation of IgG4-related disease (IgG4-RD). IgG4-RD is a chronic inflammatory disease most commonly affecting the pancreas, characterised by infiltration of IgG4-positive plasma cells and lymphocytes into various organs.<sup>1</sup> We recently encountered a male patient with IgG4-related MP who was incidentally found to have a very high level of CA-125, which correlated with CRP levels and normalised after steroid treatment. This prompted a systematic literature review (SLR) to better understand this unexpected phenomenon. <h3>Objectives</h3> To investigate for associations between CA-125, MP and/or IGG4-RD, understand possible common pathophysiological mechanisms and explore potential clinical implications. <h3>Methods</h3> The SLR was performed using MEDLINE, EMBASE, Web of Science, and Scopus, looking for literature on either MP and CA-125 or IgG4-RD and CA-125 up to January 8 2018, using a comprehensive search strategy with relevant mesh terms and keywords linked to the above broad categories. Literature screening was performed by two independent reviewers. <h3>Results</h3> 24 unique citations were found, of which 13 were unanimously identified as relevant by the two reviewers. The final selected articles included: 8 case reports, 3 conference abstracts of case reports, 1 cohort study of 22 patients, and a retrospective study of 7 patients (table 1). CA-125 was raised in 22/40 patients in the identified reports (shown in red), including males, and was often the only elevated tumour marker (yellow). We also report on the presence of effusions (blue), as this may be linked to the causal mechanism. Table 1 The clinical and laboratory characteristics of cases of IgG4-RD and MP <h3>AI</h3> <i>Autoimmune, AIH: Autoimmune Hepatitis, AIP: Autoimmune Pancreatitis, SM: Sclerosing Mesenteritis,</i> ↑<i>: Raised,</i> ↔<i>: Normal</i> <h3>Conclusions</h3> To our knowledge, this is the first SLR exploring the association between CA-125 and IgG4-RD and MP. Despite the small sample, our results do indicate that CA-125 was raised in more than 50% of reported cases, the majority of which also had some kind of effusion. Although traditionally a marker of ovarian cancer, this report highlights that a raised CA-125 can be found in other, non-malignant, inflammatory conditions, and potentially correlates with inflammatory burden. CA-125 in this setting may thus represent a useful biomarker and have a role in monitoring treatment response. <h3>Reference</h3> [1] Minato H, Shimizu J, Arano Y, et al. IgG4-related sclerosing mesenteritis: a rare mesenteric disease of unknown etiology. Pathol Int. 2012;62:281–6. <h3>Disclosure of Interest</h3> None declared
Oncostatin M induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis
Authors: Alexander E. Ide, Ryan G. Holzer, Marisa M. Queen, Andrew Oler, Amanda J. Bruesch, Randy E. Ryan, Cheryl L. Jorcyk
Journal: Cancer Research (2006)

1637  Oncostatin M (OSM), a multifunctional cytokine belonging to the IL-6 family, is produced by many cell types including human T-lymphocytes, neutrophils, macrophages and monocytes. OSM has been shown to inhibit the proliferation of breast and other tumor cell lines in vitro, and attention has been given to OSM as a potential cancer therapeutic. Recent studies, however, have shown that OSM stimulates cell detachment and invasion in vitro, and induces vascular endothelial growth factor (VEGF) in endothelial and astroglioma cells, which suggests that OSM may play a role in angiogenesis and tumor progression. Here we demonstrate that OSM induces VEGF by approximately 4-fold in several human breast cancer cell lines, including MDA-MB-231 and T47D, and that this induction is dose- and time-dependent. Additionally, we demonstrate a novel property of OSM in the up-regulation of HIF1α, a potent pro-angiogenic transcription factor, and provide new evidence that OSM-induced VEGF expression is dependent on both the STAT3 and HIF1 signaling pathways. We show that conditioned media from OSM-treated breast cancer cells enhances endothelial cell formation by ∼150%, as measured by an increase in branch points in an in vitro angiogenesis assay. In addition, OSM-induced VEGF causes dramatic in vivo neovascularization, as measured by a 12-fold increase in hemoglobin levels in a Matrigel plug assay. This is the first direct evidence that OSM-induced VEGF in human breast cancer cells occurs through activation of STAT3 and HIF1α, and has a potent pro-angiogenic effect on endothelial cells in vitro and in vivo. These results suggest the importance of designing therapeutics to inhibit OSM during breast cancer progression and subsequent metastasis.
Burden of Multiple Myeloma in Taiwan
Authors: Tzu-Chuan Huang, Jia-Hong Chen, Yi-Ying Wu
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Abstract 12887: Integrated Assessment of Bi-Ventricular Contractile Reserve Under Dobutamine Stress Offers an Incremental Prognostic Value for Patients With Dilated Cardiomyopathy
Authors: Kensuke Matsumoto, Hidekazu Tanaka, Kumiko Dokuni, Yutaka Hatani, Hiroki Matsuzoe, Keiko Hatazawa, Hiromi Toki, Hiroyuki Shimoura, Junichi Ooka, Hiroyuki Sano, Takuma Sawa, Yoshiki Motoji, Yasuhide Mochizuki, Kazuhiro Tatsumi, Ken-ihi Hirata
Journal: Circulation (2014)

Introduction: Right ventricular (RV) as well as left ventricular (LV) function, has been increasingly recognized as an important prognostic factor for heart failure patients. Hypothesis: We assesse...
Cancer patients’ and healthcare providers’ perceptions about supportive and integrative oncology services.
Authors: Cherry Jiang, Olivia Larbi, Denise Feyes, Hasina Momotaz, Ming Li, Kate Daunov, Barbara J. Daly, Susan Rose Mazanec, Samuel Rodgers-Melnick, Sarah Rolfe, Nancy Tamburro, Richard T. Lee
Journal: Journal of Clinical Oncology (2018)

100 Background: Supportive and integrative oncology services help to improve quality of life for cancer patients. This study characterizes and compares the perceptions of these services among cancer patients and healthcare providers. Methods: A cross-sectional survey was administered to Seidman Cancer Center (SCC) providers online in Spring 2018 and to SCC patients in waiting rooms March - July 2018. The survey asked about familiarity, perceived importance, frequency of use, accessibility and barriers of 19 supportive and integrative oncology services using a 5 point Likert scale. Data analysis included the Chi-square test and Spearman’s rank correlation. Results: A total of 585 surveys were obtained (421 patients and 164 healthcare providers). Patients were generally &gt; 60 (58.2%), female (57.4%), Caucasian (64.2%) with most at &gt; 1 year from starting treatment (59.9%). Healthcare providers were physicians (38.7%), RN partners (38.1%), and advanced practice providers (APPs) (23.2%). Most were female (74.3%), Caucasian (80%) and worked at SCC for &gt; 5 years (56.4%). When compared with providers, many patients were not familiar with and did not perceive the supportive and integrative oncology services as important (see table). RN partners regarded physical therapy as less important than physicians and APPs (65.5% vs. 83.9% and 82.9%), while &gt; 85% of providers from each category regarded palliative care, social work and diet &amp; nutrition services as important. The most common barrier for both patients and providers was being unaware of the services (41.6% and 67.1%). Conclusions: Overall, healthcare providers were more familiar than patients with many supportive and integrative oncology services and considered most to be more important. Being unaware of the services was a common barrier identified by both providers and patients. [Table: see text]
Sexual health in young women with metastatic breast cancer: The state of the science.
Authors: Marissa Rose Silverman, Michael W. Rabow
Journal: Journal of Clinical Oncology (2018)

223 Background: The incidence of metastatic breast cancer (MBC) in women under 40 is increasing. Sexual health is a key element of quality of life (QOL) and is impacted by MBC. While those searching the Internet receive primarily anecdotal information, the state of the science around MBC and sexual health for young women appears to be limited. Methods: Four databases were searched for English language articles: PubMed, PsycINFO, Embase, and Sociological Abstracts.Search topics included sexual health, sexual activity, intimacy, gender identity, sexual orientation, body image, and/or intimate partner relationships among young women with MBC. Results: 598 studies were reviewed; 9 met selection criteria. Four studies were included on body image and sexual activity: 2 reported a correlation between young age and poor body image; in a third, no relationship was found for women 30-49; in the fourth, among patients with metastatic or localized disease, women &lt; 45 placed greater importance on body image or changes in sex life than women &gt; 65. Three studies examined sexual health and treatment: a review of hormonal therapies in young patients recommended that sexual side effects be considered; a qualitative study reported on the impact of mastectomy on feelings of femininity and body image; an observational study of patients with locally recurrent or MBC found younger age was associated with greater vaginal dryness and decreased sexual interest/activity. One qualitative study did not find patterns of difference in sexual health needs related to age-patients of all ages and relationship status desired more information. In a study of QOL and MBC, younger age was associated with less sex life satisfaction. Subjects across all studies were primarily white, and sexual activity studied was primarily heterosexual, vaginal sex. Conclusions: The scientific literature on sexual health among young women with MBC is exceedingly limited. Studies that do examine sexual health often exclude those with MBC, do not examine the impact of age, and are focused on heterosexual, white women. Understanding the impact of MBC on young women’s sexual health can inform future care practices for this growing population.
Abstract 14613: Stroke and Death in Patients With Atrial Fibrillation After Cardiac Surgery - A Meta-analysis of Recent Literature
Authors: Alexander Crystal, Christopher Labos, Cassandr Freitas, Andrew Ha, Douglas Lee
Journal: Circulation (2017)

Introduction: Atrial fibrillation is a known risk factor for stroke and death. Post-operative atrial fibrillation (POAF) occurs in 20-40% of patients undergoing cardiac bypass surgery. The optimal ...
Health as a Way of Doing Business
Authors: Howard K. Koh, Sara J. Singer, Amy C. Edmondson
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THU0383 Performance of musculoskeletal involvement of systemic lupus erythematosis: an ultrasound study in 114 patients
Authors: Y. Geng
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Joints are commonly involved in systemic lupus erythematosus (SLE). Ultrasound (US) has been widely used in rheumatoid arthritis (RA), however rarely applied and studied in SLE. <h3>Objectives</h3> To investigate the ultrasonic changes of the symptomatic joints and their correlations with clinical manifestations in SLE patients. <h3>Methods</h3> 114 SLE patients who complained of arthralgia or arthritis from May 2014 to Aug 2017 and 15 Rhupus patients due to overlapping with RA were recruited for ultrasound evaluation. Ultrasound scan of the symptomatic joint areas was completed. The correlation between ultrasonographic changes and clinical characteristics was analysed. Besides that, US changes of bilateral wrists and hands of Rhupus patients were compared with those of the SLE patients. <h3>Results</h3> In a total of 1866 joints scanned, synovial hyperplasia, tenosynovitis, erosion and osteophytes were all observed. Synovial hyperplasia was more often observed in knees in 28.6% patients (12/42), ankles in 25% patients (7/28), wrists in 23.3% patients (23/69) and elbows in 20% patients (5/25). Tenosynovitis and erosion were most commonly found in shoulders in 35% (7/20) and 65% (13/20) patients. Osteophytes were more common in proximal interphalangeal (PIP) joints, elbows and knees. Among 69 patients with 22 joints (bilateral wrists and hands) scanned, synovial hyperplasia was observed in 25 patients (36.2%) and erosion in 22 patients (31.8%). The agreement between synovial hyperplasia and swollen joints in PIP was fair (κ=0.633, p&lt;0.01), however poor in wrists (κ=0.089, p=0.584). 18.4% patients with synovial hyperplasia had no tenderness or swollen clinically, while 15.7% patients with tenderness or swollen had no synovial hyperplasia on ultrasound. No correlation was found between ultrasound changes with SLE disease activity index. Both synovial hyperplasia and erosion were more common in Rhupus patients (73.3% vs. 36.2%, p=0.08; 66.7% vs. 26.0%, p=0.03) with significantly higher GS score (7.4±6.4 vs.1.6±4.1, p=0.04) than SLE alone patients. <h3>Conclusions</h3> Variety of changes can be observed by ultrasound at different joints in SLE patients. The ultrasonographic changes and clinical manifestations did not always correspond to each other. Synovial hyperplasia and erosion was more common in Rhupus patients. <h3>Disclosure of Interest</h3> None declared
Cloud algorithm-driven oximetry-based diagnosis of obstructive sleep apnoea in symptomatic habitually snoring children
Authors: Zhifei Xu, Gonzalo C. Gutiérrez-Tobal, Yunxiao Wu, Leila Kheirandish-Gozal, Xin Ni, Roberto Hornero, David Gozal
Journal: European Respiratory Journal (2018)

The ability of a cloud-driven Bluetooth oximetry-based algorithm to diagnose obstructive sleep apnoea syndrome (OSAS) was examined in habitually snoring children concurrently undergoing overnight polysomnography. Children clinically referred for overnight in-laboratory polysomnographic evaluation for suspected OSAS were simultaneously hooked to a Bluetooth oximeter linked to a smartphone. Polysomnography findings were scored and the apnoea/hypopnoea index (AHI PSG ) was tabulated, while oximetry data yielded an estimated AHI OXI using a validated algorithm. The accuracy of the oximeter in identifying correctly patients with OSAS in general, or with mild (AHI 1–5 events·h −1 ), moderate (5–10 events·h −1 ) or severe (&gt;10 events·h −1 ) OSAS was examined in 432 subjects (6.5±3.2 years), with 343 having AHI PSG &gt;1 event·h −1 . The accuracies of AHI OXI were consistently &gt;79% for all levels of OSAS severity, and specificity was particularly favourable for AHI &gt;10 events·h −1 (92.7%). Using the criterion of AHI PSG &gt;1 event·h −1 , only 4.7% of false-negative cases emerged, from which only 0.6% of cases showed moderate or severe OSAS. Overnight oximetry processed via Bluetooth technology by a cloud-based machine learning-derived algorithm can reliably diagnose OSAS in children with clinical symptoms suggestive of the disease. This approach provides virtually limitless scalability and should alleviate the substantial difficulties in accessing paediatric sleep laboratories while markedly reducing the costs of OSAS diagnosis.